Recently, T-cell receptors targeting mutp53-derived neoantigens are cloned and proposed as therapeutic agents.48, 49, 50, 51 Overall, these data support that cancer patients have both humoral and cellular immune responses against mutp53 in their tumors, underlying the scientific premise to develop personalized p53-targeting agents by improving natural immunity. Here, TP53 is linked to cancer.